Cannabidiol as an Adjunctive Treatment for Acute Bipolar Depression: A Pilot Study.
Jairo Vinícius PintoJosé Alexandre S CrippaKeila Maria CeresérMiréia Fortes Vianna-SulzbachÉrico de Moura Silveira JúniorGabriel Santana da RosaManoella Guatimuzim Testa da SilvaGabriel Henrique HizoLeonardo Simão MedeirosCarlos Eduardo Santana de OliveiraGiovana BristotAlline Cristina CamposFrancisco Silveira GuimarãesJaime E C HallakAntonio W ZuardiLakshmi N YathamFlávio KapczinskiMárcia K Sant'AnnaPublished in: Canadian journal of psychiatry. Revue canadienne de psychiatrie (2023)
Cannabidiol did not show significantly higher adverse effects than placebo. Despite the negative finding on the primary outcome, an exploratory analysis suggested that cannabidiol should be further studied in bipolar depression in higher doses of at least 300 mg/day and under research designs that could better control for high placebo response.